Fevipiprant - Novartis

Drug Profile

Fevipiprant - Novartis

Alternative Names: NVP-QAW-039; QAW-039; QAW39A; QAW39A2107

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles; Skin disorder therapies
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic asthma; Asthma
  • Phase II Atopic dermatitis
  • No development reported Allergic rhinitis

Most Recent Events

  • 21 Jun 2018 Novartis announces intention to submit NDA for Atopic dermatitis in 2021 (Novartis Annual Report, Jan 2017)
  • 21 Jun 2018 Novartis announces intention to submit NDA for Asthma in 2019 (Novartis Annual Report, Jan 2017)
  • 18 May 2018 Efficacy and pharmacokinetics data from a preclinical studies in Asthama presented at the 114th International Conference of the American Thoracic Society(ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top